Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (May 14, 2013)
  • 8-K (Mar 1, 2013)
  • 8-K (Feb 14, 2013)
  • 8-K (Nov 15, 2012)
  • 8-K (Nov 14, 2012)
  • 8-K (Sep 27, 2012)

 
Other

Palatin Technologies 8-K 2008

Documents found in this filing:

  1. 8-K
  2. Ex-99
  3. Graphic
  4. Graphic

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934

Date of Report (Date of earliest event reported):   June 27, 2008

Palatin Technologies, Inc.
(Exact name of registrant as specified in its charter)

Delaware

001-15543

95-4078884

(State or other jurisdiction

(Commission

(IRS employer

of incorporation)

File Number)

identification number)

4C Cedar Brook Drive, Cranbury, NJ

08512

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:  (609) 495-2200


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 1.01 Entry into a Material Definitive Agreement.

        On June 27, 2008, we entered into an amendment (the “Amendment”) to the Research Collaboration and License Agreement dated January 30, 2007 between AstraZeneca AB and us (the “Agreement”). The Agreement was previously filed as Exhibit 10.2 of our quarterly report on Form 10-Q for the quarter ended December 31, 2006, filed with the SEC on February 8, 2007. Under the Amendment, we have granted AstraZeneca the right to license certain additional compounds, patents and patent applications for use in treatment of obesity, diabetes and related metabolic syndrome, and AstraZeneca has agreed to pay milestone payments thereon contingent upon development, regulatory and sales milestones, together with royalties on sale of approved products.


Item 8.01 Other Events.

        On July 1, 2008, we issued a press release, attached hereto as Exhibit 99 and made part of this report, announcing the Amendment.


Item 9.01 Financial Statements and Exhibits.

        (d) Exhibits:


     

 

99

Press Release dated July 1, 2008



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

       

 

PALATIN TECHNOLOGIES, INC.

 

 

 

Date: July 1, 2008

By:

/s/ Stephen T. Wills

 

 

 

Stephen T. Wills, CPA, MST
Executive Vice President - Operations and
Chief Financial Officer

 

-2-




EXHIBIT INDEX


  99 Press Release dated July 1, 2008
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki